Thought Leader Liaison - Northeast
Alnylam Pharmaceuticals | |
United States, Massachusetts, Cambridge | |
675 West Kendall Street (Show on map) | |
Nov 13, 2024 | |
Overview
We are looking for an experienced Thought Leader Liaison to support the promotion of AMVUTTRA (vutrisiran). The Thought Leader Liaison (TLL) is a commercial, field-based, customer facing role primarily focused on the identification and development of enduring relationships with both current and emerging key opinion leaders (KOLs). S/he will focus on engaging KOLs to solicit insights and develop advocacy aligned to commercial and marketing strategy and messaging. As integral strategic partners to Alnylam's internal and field-based teams, TLLs support cross functional, commercial opportunities and engagements with KOLs including marketing education initiatives, advisory boards, speakers bureau strategy, congress strategy, and consulting opportunities. Additionally, the TLL helps to inform commercial and marketing strategy, messaging, and resources through the sharing of insights and connecting KOLs with Alnylam cross functional partners. The TLL role will work closely and collaboratively with internal partners including marketing, medical affairs, sales, legal, and compliance to maintain KOL coordination but also to manage appropriate distinction of roles and boundaries among the expertise areas. Our team is at the forefront of commercializing an industry-leading TTR Franchise, with a focus on preparing for the potential launch of Vutrisiran in cardiomyopathy while continuing to establish market leadership for ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) in polyneuropathy. If approved, Vutisiran is anticipated to emerge with a market-leading profile in ATTR-CM, offering a unique mechanism of action and the potential for a highly impactful clinical profile in a rapidly growing market with significant unmet patient needs.. Key Responsibilities
Qualifications Education: Bachelor's degree; sience degree preferred. Experience:
Additional Requirements:
About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. > |